Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) had its target price lifted by equities researchers at Mizuho from ...

Truist Securities adjusted their financial outlook for Axsome Therapeutics (NASDAQ:AXSM), increasing the price target to $190 from the previous $180 while maintaining a Buy rating on the company's ...

January's other major leases included KnitWell Group renewing and expanding to about 246,000 square feet at 7 Times Square, A ...

Truist analyst Joon Lee raised the firm’s price target on Axsome Therapeutics (AXSM) to $190 from $180 and keeps a Buy rating on the shares.

Truist Financial analyst Joon Lee reiterated a Buy rating on Axsome Therapeutics (AXSM – Research Report) today and set a price target of ...

Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS ...

The US Food and Drug Administration FDA has approved Symbravo, an oral combination of meloxicam and rizatriptan, for the ...

Royal Bank of Canada reaffirmed their outperform rating on shares of Axsome Therapeutics (NASDAQ:AXSM – Free Report) in a report published on Wednesday morning,Benzinga reports. They currently have a ...

The FDA approved an oral combination of meloxicam and rizatriptan (Symbravo) to treat adults with acute migraine with or ...

The Food and Drug Administration (FDA) has approved Symbravo ® (meloxicam/rizatriptan) for the acute treatment of migraine with or without aura in adults.

An effort two decades in the making, Vertex Pharmaceuticals Inc.’s suzetrigine gained U.S. FDA approval as the first drug targeting the NaV1.8 pain signal. Branded Journavx, the oral small molecule is ...

The FDA approves AXSM's Symbravo for the acute treatment of migraine with or without aura in adults. The latest nod diversifies its commercial portfolio.